Skip to content

Clinical study on probiotics alleviating adverse reactions in anti-tumor treatment of lung cancer

Clinical study on probiotics alleviating adverse reactions in anti-tumor treatment of lung cancer

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078900
Enrollment
Unknown
Registered
2023-12-20
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Sponsors

Weihai Municipal Hospital Affiliated to Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age: 18-75 years old; (2) Meets the diagnostic criteria for lung cancer; (3) The condition is temporarily stable and medication can control the stage; (4) Informed and willing to participate in research and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnant women or lactating patients; (2) Female patients who have not used any contraceptive measures; (3) Patients with unstable vital signs and unstable conditions; (4) Patients with concomitant other lung diseases; Such as acute lung infection, chronic obstructive pulmonary disease, bronchial asthma, pulmonary embolism, bronchiectasis, etc; (5) Concomitant with other active malignant tumors, stroke, myocardial infarction, and other serious primary diseases; (6) Patients with a history of gastrointestinal diseases such as gastrointestinal bleeding, irritable bowel syndrome, Crohn's disease or ulcerative colitis, and a history of gastrointestinal surgery; (7) Patients with a history of mental illness; (8) Patients who have taken antibiotics, glucocorticoids or other immunosuppressive agents, foods or drugs containing probiotics or prebiotics within the past month; (9) Individuals who are allergic to the test sample or exhibit obvious gastrointestinal symptoms such as intolerance; (10) Simultaneously receiving other clinical trial patients; (11) Those who have been determined by the researcher to be unable to complete the research on time.

Design outcomes

Primary

MeasureTime frame
Gastrointestinal Symptom Scale (GSRS);

Secondary

MeasureTime frame
EORTC QLQ-C30 version 3.0 and QLQ-LC13 ;

Countries

China

Contacts

Public ContactLiu Ailing

Weihai Municipal Hospital Affiliated to Shandong University

liuailing0730@163.com+86 186 6037 7730

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026